Displaying drugs 11126 - 11150 of 12049 in total
ETBX-011
ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
Investigational
Matched Description: … ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen …
RTL-1000
RTL-1000 is a recombinant T-Cell receptor ligand being investigated for the treatment of multiple sclerosis.
Investigational
Matched Description: … RTL-1000 is a recombinant T-Cell receptor ligand being investigated for the treatment of multiple sclerosis …
TLY-012
TLY-012 is a PEGylated recombinant human tumor necrosis factor-related apoptosis-inducing ligand (PEGylated TRAIL).
Investigational
Matched Description: … TLY-012 is a PEGylated recombinant human tumor necrosis factor-related apoptosis-inducing ligand (PEGylated …
IDUA-RTB
RTB-IDUA is a fusion protein of alpha-L-iduronidase (IDUA) and ricin transport subunit B (RTB).
Investigational
Matched Description: … RTB-IDUA is a fusion protein of alpha-L-iduronidase (IDUA) and ricin transport subunit B (RTB). …
Calpurbatug
Calpurbatug (TRL1068) is a high-affinity and broad-spectrum human antibody that targets and disintegrates bacterial biofilm.
Investigational
Matched Description: … Calpurbatug (TRL1068) is a high-affinity and broad-spectrum human antibody that targets and disintegrates …
HZT-501
HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. HZT-501 is a combination product including ibuprofen and the acid reducing...
Investigational
Matched Description: … ., a privately held biopharmaceutical company. ... HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. …
OPC-51803
OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of...
Investigational
Matched Description: … It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple …
Bardoxolone
Bardoxolone has been used in trials studying the treatment of LYMPHOMA and Solid Tumors. It is a synthetic triterpenoid and a highly potent activator of redox-sensitive signaling pathways that induce programmed cell death (apoptosis) in cancer cells that are under high levels of intrinsic oxidative stress. In contrast, Bardoxolone in...
Investigational
Matched Description: … It is a synthetic triterpenoid and a highly potent activator of redox-sensitive signaling pathways that …
Dexchlorpheniramine
Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions. It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine...
Experimental
Investigational
Matched Description: … Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. ... The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug …
OAV201
OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter. It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical...
Investigational
Matched Description: … OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human ... Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter …
ENMD-1198
Investigational
Briakinumab
Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple...
Investigational
Matched Description: … Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of ... Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and …
PRX-07034
Investigational
TM30339
TM30339 is an analogue of the natural hormone Pancreatic Polypeptide (PP), which is released in connection with meals. TM30339 works through the same receptor as the natural satiety hormone, Pancreatic Polypeptide (PP), but TM30339 has improved properties compared with PP. TM30339 thus imitates a natural mechanism, a satiety signal from...
Investigational
Matched Description: … TM30339 thus imitates a natural mechanism, a satiety signal from the gastrointestinal system involved …
Kitasamycin
Kitasamycin is a macrolide antibiotic derived from Streptomyces kitasatoensis.
Experimental
Matched Description: … Kitasamycin is a macrolide antibiotic derived from Streptomyces kitasatoensis. …
CPGJ602
CPGJ602 is a recombinant anti-EGFR human-mouse chimeric monoclonal antibody.
Investigational
Matched Description: … CPGJ602 is a recombinant anti-EGFR human-mouse chimeric monoclonal antibody. …
MDX-018
MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD)...
Investigational
Matched Description: … MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin- ... Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. ... HuMax-Inflam was also effective in reducing disease activity in palmoplantar pustulosis patients in a …
Prinomastat
Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier.
Investigational
Matched Description: … As a lipophilic agent, prinomastat crosses the blood-brain barrier. ... Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune ... It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction …
Eldecalcitol
Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Eldecalcitol, effectively and safely increased lumbar and hip bone mineral density (BMD) in osteoporotic patients who also received vitamin D3 supplementation.
Investigational
Matched Description: … Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol …
DP-b99
DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.
Investigational
Matched Description: … DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N ... ,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment …
Edivoxetine
Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment. Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.
Investigational
Matched Description: … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under …
Displaying drugs 11126 - 11150 of 12049 in total